FDA Issues Class II Recall of Sumatriptan Injection Due to Temperature Exposure
McKesson Medical-Surgical is recalling Sumatriptan Injection, USP, 6mg/0.5mL nationwide due to temperature abuse during distribution that may have affected medication stability and potency.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall with no reported illnesses or injuries. Temperature abuse of an injectable medication presents potential risk-of-harm through stability degradation and loss of potency, but no adverse health consequences have been documented in the source.
Plain-English summary
Sumatriptan Injection, USP, 6mg/0.5mL packaged in boxes of 5 single-dose vials is being recalled. The product is manufactured by Auromedics Pharma LLC and distributed by McKesson Medical-Surgical Inc.
The recall was issued because of cGMP deviations involving temperature abuse. Temperature exposure during distribution may have affected the medication's stability and potency.
The recall affects Sumatriptan Injection distributed nationwide. Patients and healthcare facilities that received this product should determine whether their supply is affected by reviewing their distribution records.
If you have questions or concerns about your supply, contact McKesson Medical-Surgical Inc. or your healthcare provider. Patients should not discontinue use without consulting their healthcare provider.
The recalled product
- Product
- Sumatriptan Injection, USP, 6mg/0.5 mL, packaged in a box of 5 x 0.5 mL single-dose vials, Rx only, Manufacturer: Auromedics Pharma LLC, NDC 55150-0173-01
- Manufacturer
- Mckesson Medical-Surgical Inc. Corporate Office
- Category
- Drug — Injectable Medication
- Hazard
- temperature-abuse
- stability-degradation
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27